Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma (BBIO) is a biopharmaceutical innovator developing genetic disease therapies through its unique portfolio-based approach. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and stakeholders gain centralized access to critical updates including clinical milestones, regulatory filings, financial disclosures, and research partnerships. Our curated feed ensures timely tracking of therapeutic advancements across BridgeBio's diversified pipeline.
Key focus areas include progress in Mendelian disorder treatments, oncology targets, and gene therapy innovations. All content undergoes strict verification to maintain compliance with financial disclosure standards and medical accuracy guidelines.
Bookmark this page for efficient monitoring of BBIO's scientific advancements and corporate developments. Combine this resource with SEC filings and earnings transcripts for comprehensive investment analysis.
BridgeBio Pharma (Nasdaq: BBIO) has forged a three-year collaboration with the Salk Institute to advance research in genetically driven diseases, particularly in oncology. This partnership aims to translate innovative academic discoveries into therapeutic applications. Salk's cancer research will receive funding, facilitating the development of targeted therapies. Both organizations emphasize the importance of collaboration in accelerating scientific advancements and improving patient outcomes. This alliance marks a significant step in bridging academia and industry for impactful medical innovations.
BridgeBio Pharma (Nasdaq: BBIO) has announced plans to acquire all outstanding shares of Eidos Therapeutics (Nasdaq: EIDX) that it does not already own, equating to approximately 36.3% of Eidos’ shares. Eidos shareholders may choose either 1.85 shares of BridgeBio stock or $73.26 cash per share, with a cash limit of $175 million. This acquisition aims to streamline operations and utilize BridgeBio's development infrastructure to advance Eidos’ acoramidis, a treatment for ATTR, enhancing value for both patients and investors. The transaction is expected to close in Q1 2021, pending shareholder approval.
BridgeBio Pharma announced the FDA's acceptance of its New Drug Application (NDA) for fosdenopterin (previously BBP-870/ORGN001), targeting molybdenum cofactor deficiency (MoCD) Type A. This therapy is the first of its kind, addressing a condition with no approved treatments that often leads to severe neurological injury in children. The NDA has been granted Priority Review, with prior designations including Breakthrough Therapy and Rare Pediatric Disease. This marks BridgeBio's first NDA acceptance, indicating progress in developing vital treatments for rare genetic diseases.
BridgeBio Pharma has announced that the FDA has accepted its New Drug Application (NDA) for fosdenopterin for treating molybdenum cofactor deficiency (MoCD) Type A, a condition with no approved therapies. The NDA is designated for Priority Review and has previously received Breakthrough Therapy and Rare Pediatric Disease Designations. Fosdenopterin is aimed at addressing severe neurological injuries in infants, with median survival of less than four years. This marks BridgeBio's first NDA acceptance, highlighting its commitment to developing treatments for genetic diseases.
BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases and cancers, will host its first R&D Day on September 29 at 8:30 am E.T. The virtual event will showcase presentations from BridgeBio's leadership and external experts. Key focus areas include the company’s drug engineering platform and targeted oncology portfolio, with four highlighted programs expected to present clinical data in the next 12-24 months: acoramidis for transthyretin amyloidosis, low-dose infigratinib for achondroplasia, AAV5 gene therapy for congenital adrenal hyperplasia, and encaleret for autosomal dominant hypocalcemia type 1.
BridgeBio Pharma's affiliate, Calcilytix Therapeutics, has initiated a Phase 2 study for encaleret (CLTX-305), targeting ADH1, a rare genetic condition causing low serum calcium levels. The study, conducted at the NIH, aims to enroll 16 participants to assess the drug’s safety and efficacy. Currently, there are no approved treatments for ADH1, with conventional therapies often exacerbating symptoms. Topline proof-of-concept results are anticipated in 2021, aiming to address significant unmet medical needs for patients suffering from this debilitating disorder.
BridgeBio Pharma (Nasdaq: BBIO) announced on September 1, 2020, the granting of options to purchase 18,231 shares and restricted stock units for 19,915 shares under its 2019 Inducement Equity Plan. The compensation committee made these grants to 10 new employees as an inducement for their employment, adhering to Nasdaq Listing Rule 5635(c)(4). These awards are part of BridgeBio's effort to attract talent as it advances its pipeline of over 20 programs targeting genetic diseases and cancers with genetic drivers.
BridgeBio Pharma (Nasdaq: BBIO) announced the grant of stock options and restricted stock units to 22 employees on August 3, 2020. The total awards comprise options for 30,443 shares and restricted units for 61,760 shares, with an exercise price of $27.20 per share. These grants are part of the 2019 Inducement Equity Plan, established to incentivize new employees under Nasdaq Listing Rule 5635(c)(4). Founded in 2015, BridgeBio focuses on developing transformative medicines for genetic diseases, holding a diverse pipeline of over 20 programs.
BridgeBio Pharma (Nasdaq: BBIO) reported second-quarter results for 2020, achieving significant milestones in its clinical pipeline and collaborations. The company initiated four clinical trials and submitted three IND applications to the FDA, with a reported cash position of $840.9 million as of June 30, 2020. BridgeBio expanded its global presence through a partnership with LianBio, focusing on oncology, with potential payments of $26.5 million upfront and up to $505 million in future milestones. Operating expenses increased to $124.6 million, resulting in a net loss of $136.2 million for the quarter.
BridgeBio Pharma (NASDAQ: BBIO) announces a strategic partnership with LianBio to expand its presence in China, a significant pharmaceutical market. The collaboration involves initial $26.5 million in payments and potential future milestones of up to $505 million. It focuses on the development of FGFR inhibitor infigratinib and SHP2 inhibitor BBP-398 for cancers with genetic mutations. BridgeBio aims to address patient needs in Asia by leveraging LianBio's local access and expertise. CEO Neil Kumar joins LianBio's board, reinforcing their partnership.
